Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. presented new analyses from its varoglutamstat Phase 2 program at the World Congress of Nephrology, reinforcing the potential of glutaminyl cyclase inhibition for diabetic kidney disease (DKD). Data from the VIVIAD and VIVA-MIND studies showed consistent improvements in kidney function, particularly in elderly participants with diabetes and those with lower baseline eGFR (mean 60 mL/min/1.73m²). Furthermore, a DKD mouse model demonstrated significant reductions in inflammation, glomerulosclerosis, and improved kidney function, supporting varoglutamstat's development for more advanced CKD stages.

Disclaimer*

UK 100

Latest directors dealings